CBLS - ETF AI Analysis
Top Page
Changebridge Capital Long/Short Equity ETF (CBLS)
Rating:57Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has delivered solid gains so far this year and in recent months, showing positive momentum.
High-Performing Tech Holdings
Several major technology positions, including chip and semiconductor-related names, have shown strong performance and are helping drive returns.
Focused Sector Exposure
A meaningful tilt toward technology and consumer-related companies gives the fund exposure to areas of the market that have been performing well.
Negative Factors
Very High Expense Ratio
The fund charges a much higher fee than many other ETFs, which can eat into investor returns over time.
Concentration in a Few Stocks and Sectors
A large share of assets is tied up in a handful of technology names and related sectors, increasing the impact if these areas stumble.
Heavy U.S. Market Dependence
With most of its holdings in U.S. companies and very limited foreign exposure, the ETF is highly sensitive to the U.S. stock market’s ups and downs.
CBLS vs. SPDR S&P 500 ETF (SPY)
AUM60.27M
RegionNorth America
Expense Ratio1.89%
Beta0.63
IssuerClough
Inception DateNov 13, 2020
Dividend Yield0.74%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume5,700
30 Day Avg. Volume3,400
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
36.55Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering40
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CBLS Summary
CBLS is the Changebridge Capital Long/Short Equity ETF, which uses an active, hedge-fund-style strategy rather than tracking a set index. It invests mainly in U.S. stocks across many sectors, with a big focus on technology. The fund can buy companies it expects to rise and also bet against stocks it expects to fall. Well-known holdings include Alphabet (Google’s parent company) and Broadcom. Someone might invest for potential growth and diversification, since it can try to profit in both rising and falling markets. A key risk is that this complex strategy is still a stock fund, so its value can go up and down significantly.
How much will it cost me?The Changebridge Capital Long/Short Equity ETF (CBLS) has an expense ratio of 1.9%, which means you’ll pay $19 per year for every $1,000 invested. This is higher than average because it is actively managed, employing a hedge fund-like strategy to navigate complex markets and optimize returns.
What would affect this ETF?The Changebridge Capital Long/Short Equity ETF (CBLS) could benefit from growth in the technology sector, which makes up a significant portion of its holdings, as well as strong performance from top companies like Microsoft and Nvidia. However, rising interest rates or economic slowdowns could negatively impact consumer cyclical and financial sectors, which are also key exposures for the fund. Additionally, regulatory changes or geopolitical tensions affecting North American markets could pose risks to its U.S.-focused investments.
CBLS Top 10 Holdings
CBLS is leaning into a U.S.-heavy mix of health care and consumer names, with a dash of tech-driven growth. High-flyers like 10x Genomics and Krystal Biotech have been doing the heavy lifting, giving the fund a biotech-flavored boost, while Oscar Health and ImmunityBio add more speculative, but rising, health care exposure. On the consumer side, Starbucks looks steady but not sprinting, and Service International and Pool have been lagging, acting like a bit of ballast. Overall, the fund feels concentrated in U.S. health care innovation with selective consumer bets.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| 10x Genomics | 3.13% | $1.87M | $4.41B | 205.28% | 60 Neutral | |
| Tenable Holdings | 3.07% | $1.83M | $2.96B | -21.30% | 61 Neutral | |
| Krystal Biotech | 3.02% | $1.80M | $10.26B | 149.01% | 80 Outperform | |
| Service International | 2.99% | $1.79M | $10.03B | -7.90% | 67 Neutral | |
| Starbucks | 2.99% | $1.78M | $114.71B | 8.46% | 56 Neutral | |
| ImmunityBio | 2.98% | $1.78M | $7.71B | 161.59% | 48 Neutral | |
| Astera Labs, Inc. | 2.76% | $1.65M | $71.49B | 411.53% | 68 Neutral | |
| Select Energy Services | 2.74% | $1.64M | $2.49B | 108.58% | 62 Neutral | |
| Rollins | 2.70% | $1.61M | $21.65B | -22.26% | 79 Outperform | |
| Solaris Energy Infrastructure | 2.68% | $1.60M | $6.10B | 196.54% | 69 Neutral |
CBLS Technical Analysis
Positive
―
Price Trends
32.52
Positive
31.18
Positive
29.75
Positive
Market Momentum
0.33
Negative
60.73
Neutral
80.33
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For CBLS, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 33.27, equal to the 50-day MA of 32.52, and equal to the 200-day MA of 29.75, indicating a bullish trend. The MACD of 0.33 indicates Negative momentum. The RSI at 60.73 is Neutral, neither overbought nor oversold. The STOCH value of 80.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CBLS.
CBLS Peer Comparison
Comparison Results
Performance Comparison
CBLS
Changebridge Capital Long/Short Equity ETF
33.26
5.05
17.90%
STNC
Stance Equity ESG Large Cap Core ETF
―
―
―
BAMD
Brookstone Dividend Stock ETF
―
―
―
SOVF
Sovereign's Capital Flourish Fund
―
―
―
YALL
God Bless America ETF
―
―
―
RFDA
RiverFront Dynamic US Dividend Advantage ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents